Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Slides:



Advertisements
Similar presentations
Figure 1. Higher prevalence of significant GER symptoms in patients with COPD. The prevalence of significant GER symptoms (heartburn and/or regurgitation.
Advertisements

1 Literature Review Peter R. McNally, DO, FACP, FACG Lone Tree, Colorado.
Refractory Heartburn: When PPI’s Fail to Sooth the Burn
Strategies to Switch Antidepressants Brittany Parmentier, PharmD PGY2 Behavioral Care Resident Butler University/Community Health Network This speaker.
New Techniques and Perspectives Presented on: May 17th 2014
Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum Question.
Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors F Zerbib, A Duriez, S Roman, M.
D. Kiagiadaki, V. Bachy, M. Remacle, S. Van Der Vorst, G. Lawson
Pathophysiology Factors associated with development of GERD:
Refractory GERD Aaron Sinclair, MD
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 3 Low-grade inflammation in FGID
Contribution by: Prof. Dr. J.J. Kolkman
Figure 2 Enteroids can model transport physiology
Figure 1 Imaging of a depressed intramucosal carcinoma
Figure 4 Activation of clopidogrel via cytochrome P450
Figure 5 Therapeutic paradigms for interfering with the brain–gut axis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 7 Treatment algorithm for perianal fistulizing disease
Clinical algorithm for the diagnosis of chronic cough.
Figure 7 Management algorithm for patients with ACLF
Figure 5 Lipid droplet consumption
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Biosimilar development process
Michael F. Vaezi, David Katzka, Frank Zerbib 
Figure 3 Algorithm from working group describing
Figure 2 Effect of PPIs on gastric physiology
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 6 Combination therapy for HCC
Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.
Figure 1 Definition and concept of ACLF
Figure 2 Switching of biologic agents and biosimilars
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
to the liver and promote patient-derived xenograft tumour growth
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 7 Example colonic high-resolution manometry
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure legend Serum cholesterol concentration (mg/dL)
Figure 1 Environmental factors contributing to IBD pathogenesis
Figure 4 Examples of reflux episodes on pH and pH-impedance monitoring
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.
in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)
Figure 6 Possible therapeutic targets to decrease hepatic steatosis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 5 High-resolution manometry studies performed
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
William K. Fackler, Tina M. Ours, Michael F. Vaezi, Joel E. Richter 
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 6 Assessment of colonic transit time with radiopaque markers
Figure 5 Systems biological model of IBS
Radu Tutuian, Donald O Castell 
Figure 5 PPIs and adverse events with proven and unproven causality
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Lifelong influences on the gut microbiome from
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Current Diagnosis and Management of Suspected Reflux Symptoms Refractory to Proton Pump Inhibitor Therapy Joel E. Richter, M.D. Gastroenterology & Hepatology.
Presentation transcript:

Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.50 Figure 4 Current management algorithm for typical rGERD symptoms in the opinion of the authors, accounting for access to MII-pH monitoring Figure 4 | Current management algorithm for typical rGERD symptoms in the opinion of the authors, accounting for access to MII-pH monitoring. Endoscopic treatments have not been added to the algorithm because of inconclusive evidence on their efficacy in patients with rGERD. *Typical GERD symptoms are heartburn and/or regurgitation not located in the epigastrium (dyspepsia) or the throat area. ‡Baclofen is started at 5 mg three times a day before meals, and increased to 10 mg three times a day after 1 week. Therapeutic effectiveness can be evaluated after one month. Up-titration to 20 mg three times a day can be considered in case of good tolerance and partial efficacy of lower doses. §A neuromodulator can be a tricyclic antidepressant, for example, nortriptyline 25–50 mg in the evening, or a selective serotonin reuptake inhibitor, for example, citalopram 20 mg or fluoxetine 20 mg in the morning. ||Baclofen in the evening is started at 5 mg at bedtime, and can be increased to 10 mg or 20 mg. Therapeutic effectiveness can be evaluated after one month. ¶pH monitoring on and off PPI therapy can provide additional evidence before deciding on antireflux surgery. #A properly blinded acid perfusion test can inform the decision of whether to perform antireflux surgery, yet a positive test should not be considered definitive evidence that surgery should be undertaken. MII–pH, multichannel intraluminal impedance and pH monitoring; rGERD, refractory GERD. Scarpellini, E. et al. (2016) Management of refractory typical GERD symptoms Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.50